The United States has seen a possible turning point in its long-standing obesity epidemic with evidence suggesting a decline in obesity rates since 2023. According to a study by Benjamin Rader and his colleagues, who analyzed data from over 16 million adults, there was a decline in obesity prevalence for the first time in more than 10 years. The use of new weight loss medications such as Ozempic, Wegovy, and Zepbound has quadrupled between 2021 and early 2026, with many patients experiencing significant weight loss. Researchers are divided on whether this decline is temporary or a sign of a long-term shift in obesity rates.
Written by the local model on 2026-08-24,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
The United States has been grappling with an obesity epidemic since the late 1970s, but there is growing evidence that the constantly climbing obesity rates are beginning to drop.
asserted
rates → grapple → 1970s
"We're seeing signs that there's going to be a turning point," said Benjamin Rader, an epidemiologist at Boston Children's Hospital and at Harvard Medical School who conducts research into health trends using large datasets.
asserted
who → see → datasets
In 2024, he and his colleagues published a study based on data from more than 16 million adults, which suggested there had been a decline in obesity prevalence in 2023 — for the first time in more than 10 years.
uncertain
which → publish → years
The National Health and Nutrition Examination Survey also indicated a slight decline between 2021 and 2023.
asserted
Survey → indicate → 2021
More recent surveys have also provided evidence of declining figures.
asserted
surveys → provide → figures
Use of Ozempic, Wegovy and Zepbound skyrockets
This comes as a series of new drugs, which some people are using for weight loss, have come onto the market.
asserted
people → skyrocket → market
The use of the GLP-1 agonist drugs Ozempic, Wegovy and Zepbound has increased rapidly in recent years in the US, with prescriptions more than quadrupling between 2021 and early 2026.
asserted
prescriptions → increase → 2021
Some of the active ingredients in these drugs were originally developed to treat Type 2 diabetes by mimicking a naturally occurring intestinal hormone to promote a feeling of fullness and to slow down gastric emptying.
asserted
Some → develop → emptying
This has led to many patients losing a significant amount of weight.
asserted
patients → lead → weight
For Rader, "it seemed like it [the impact of this medicine] was bound to show up in the data" and that it was possible to be "moderately confident that drugs themselves were having an effect."
asserted
drugs → seem → effect
'Strong evidence showing significant decline in obesity'
For Peminda Cabandugama, an endocrinologist and spokesperson for The Obesity Society, which provides support to professionals in the obesity field, "there is strong evidence showing that there is a significant decline in obesity."
asserted
which → show → obesity
In a written statement to DW, he said the "general opinion is that GLP-1 medications and their combinations and their increased use as well as the recent attention put on the importance of weight management have played a large and direct role in this reduction in obesity prevalence."
But for Rader there is no definitive proof of a causal relationship.
asserted
medications → write → relationship
He has no doubt that the drugs have led to weight loss in many people at an individual level, but he told DW that it was too soon to say whether it "will lead to a plateau, […] a decrease […] or a slower decrease in the next 20 years" and what the effect on the general population might be.
uncertain
effect → have → population
Cabandugama thinks the current figures might also have been influenced by lifestyle changes during and after the COVID-19 pandemic, and points out that "these trends are likely a confluence of multiple elements that include the increased use of anti-obesity medications, post-pandemic behavioral changes, increased awareness about the importance of weight management etc."
Is the decline temporary?
uncertain
decline → think → management
Some researchers in the US don't believe obesity rates will decline permanently.
asserted
rates → believe → US
A study by the Institute of Health Metrics and Evaluation (IHME) at the University of Washington in Seattle predicts a rise in rates through 2035 and suggests that the proportion of obese adults could increase from 42.5% in 2022 to 46.9% in 2035.
uncertain
proportion → predict → 2035
Though Rader doesn't necessarily consider such predictions to be wrong, he pointed out that many prediction models are based on data from before the boom in GLP-1 drugs and might not take into account their potential effects.
uncertain
models → consider → effects
In an article for the Journal of the American Medical Association, he warned that the models could overestimate the future burden of obesity.
uncertain
models → warn → obesity
The authors of the IHME study have not entirely dismissed this criticism, but they did point out that to date only a small proportion of obese people use such drugs and that many patients discontinue treatment within a year.
asserted
patients → dismiss → year
They added that some people gain weight again after initially losing it, and more representative data was needed to assess whether such drugs will have a lasting effect on obesity rates.
asserted
drugs → add → rates
Cabandugama has also urged caution, saying that while there are currently strong signs of a decline, "the general consensus is that it is still too early to tell whether this is a true trend reversal."
Consequences of decline in obesity rates would be far-reaching
Though for a long time, obesity was viewed primarily as a result of an individual's lifestyle, it has since become well-known that this complex chronic condition is caused by a combination of biological, genetic, social and psychological factors.
asserted
condition → urge → factors
If the US were at a turning point, the consequences would be far-reaching.
asserted
consequences → reach → point
Weight loss in obese people does not only reduce their risk of related health problems, but also contributes to greater mobility, more independence and a higher quality of life.
asserted
loss → reduce → life
For Cabandugama, "the health outcomes to improve first would be betterments in cardiometabolic parameters: blood glucose levels (Type 2 diabetes mellitus), cardiovascular outcomes, fatty liver, obstructive sleep apnea etc.," which in the long term could also reduce pressure on the healthcare system.
uncertain
which → improve → system
Regardless of whether rates are on the decline, Rader said "obesity still remains a huge public health crisis in America that deserves attention, deserves funding, and deserves alternative solutions, especially as we think about how GLP-1s are not accessible to all Americans based on price and other factors.
asserted
GLP-1s → say → price
"A turning point does not mean that we're suddenly in the clear and that we don't have to worry about this thing anymore," he said.
asserted
he → mean → thing
This article was originally published in German.
asserted
article → publish → German
